News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

pSivida Corp (PSDV) Reports Australia/New Zealand Distribution Agreement For ILUVIEN® For DME


4/28/2014 10:48:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has signed an exclusive agreement with Specialised Therapeutics Australia (STA) for the distribution in Australia and New Zealand of ILUVIENĀ® for the treatment of diabetic macular edema (DME). Under the agreement, STA also will handle all regulatory and commercial activities for ILUVIEN in those countries.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES